Regeneron’s AMD Drug Gets Priority Review With FDA

Xconomy New York — 

The FDA has granted priority review status to Regeneron Pharmaceuticals’ (NASDAQ: REGN) experimental treatment for age-related macular degeneration (AMD), according to a press release. The drug, called VEGF Trap-Eye, is specifically designed to treat the neovascular form of the disease, which is commonly known as “wet AMD.” The target date for the FDA to hand over its verdict to the Tarrytown, NY-based company is August 20.